Researchers Identify New Target for Prostate Cancer
A new study reveals that targeting the HDAC4 protein can help inhibit tumor growth in aggressive prostate cancer models.
Updated on Oct. 26, 2026 in Cancer
Researchers have identified HDAC4 as a critical therapeutic target for metastatic castration-resistant prostate cancer. The study demonstrates that inhibiting this protein can suppress tumor progression and induce cell cycle arrest.
Why it matters
HDAC4 drives disease progression by silencing genes that normally prevent tumor growth and by activating signaling pathways linked to survival. This discovery provides a potential new strategy for treating aggressive prostate cancer that has become resistant to standard hormone therapies.
Treatment with the inhibitor LMK-235 induces cell cycle arrest at the G0/G1 phase and shows higher cancer-cell selectivity in AR-negative models than SAHA. These findings ground the potential for targeted protein inhibition in therapy.
The players
HDAC4
This is a protein identified as a major driver of proliferation and survival in castration-resistant prostate cancer cells.
LMK-235
This chemical inhibitor works to block the activity of HDAC4 and HDAC5 to reduce tumor growth in preclinical models.
The details
The research shows that HDAC4 forms a complex with HDAC2 and YY1 to silence the CDKN1B promoter, which normally suppresses cancer cells. By using LMK-235 to disrupt this complex and inhibit HDAC4 and HDAC5 activity, the team successfully reactivated CDKN1B expression and triggered apoptosis.
Timeline
October 26, 2026: The research findings were published.
Health Landscape
This research contributes to the ongoing development of epigenetic therapies for oncology by identifying a novel regulatory complex within cancer cells. It expands the current scientific understanding of how protein silencing mechanisms can be reversed to halt tumor progression.
This preclinical discovery offers a promising new direction for developing therapies that could eventually assist patients who no longer respond to traditional hormone-based treatments. Because the research is in the laboratory phase, these findings do not yet change current clinical standards of care.
The takeaway
This discovery highlights the importance of targeting specific protein complexes to reactivate tumor-suppressive genes in resistant cancers. Future research will focus on how such inhibitors can be safely transitioned into therapeutic applications for humans.
Further reading
Learn more about the latest research in the Cancer section.
More information
Read the complete peer-reviewed research article for detailed technical specifications.
Source note: This article includes information reported by Nature.
